Role of pertuzumab in the treatment of HER2-positive breast cancer
Authors:
Open Access
- 1 May 2012
- journal article
- review article
- Published by Taylor & Francis in Breast Cancer: Targets and Therapy
- Vol. 4, 65-73
Abstract
Peer reviewed article authored by (Hubalek M, Brantner C, Marth C). Read article or submit your manuscript for publishing.Keywords
This publication has 28 references indexed in Scilit:
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Adjuvant Trastuzumab in HER2-Positive Breast CancerNew England Journal of Medicine, 2011
- Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast CancerJournal of Clinical Oncology, 2010
- Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab TherapyJournal of Clinical Oncology, 2010
- Flow Cytometric FRET Analysis of erbB Receptor Interaction on a Cell‐by‐Cell BasisAnnals of the New York Academy of Sciences, 2008
- Combination Treatment with Erlotinib and Pertuzumab against Human Tumor Xenografts Is Superior to MonotherapyClinical Cancer Research, 2005
- The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer CellsCancer Research, 2004
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003
- Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2–ErbB3 receptorsNature Medicine, 2002
- Neuregulins Promote Survival and Growth of Cardiac MyocytesJournal of Biological Chemistry, 1998